KMDA vs. ERAS, VRCA, XOMA, FBLG, ENTA, ORGO, AVIR, CRMD, SBTX, and NLTX
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Erasca (ERAS), Verrica Pharmaceuticals (VRCA), XOMA (XOMA), FibroBiologics (FBLG), Enanta Pharmaceuticals (ENTA), Organogenesis (ORGO), Atea Pharmaceuticals (AVIR), CorMedix (CRMD), Silverback Therapeutics (SBTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Kamada (NASDAQ:KMDA) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Kamada has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Kamada has a net margin of 5.81% compared to Erasca's net margin of 0.00%. Kamada's return on equity of 5.66% beat Erasca's return on equity.
Kamada received 293 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 64.98% of users gave Kamada an outperform vote while only 60.00% of users gave Erasca an outperform vote.
Kamada currently has a consensus price target of $11.00, suggesting a potential upside of 92.64%. Erasca has a consensus price target of $7.83, suggesting a potential upside of 254.45%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than Kamada.
In the previous week, Kamada and Kamada both had 2 articles in the media. Erasca's average media sentiment score of 1.92 beat Kamada's score of 0.00 indicating that Erasca is being referred to more favorably in the news media.
Kamada has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
20.4% of Kamada shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 29.8% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Kamada beats Erasca on 11 of the 16 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
